Cardiorenal Syndrome And Current Therapies {#s1}
==========================================

Cardiorenal syndrome (CRS) is a condition that describes interdependent disease conditions where a primary dysfunctional organ causes dysfunction in a secondary organ, in this case, the heart and the kidneys ([@B70]; [@B7]). In an attempt to classify CRS, Ronco et al. defined five different subtypes in 2008 ([@B65]). In CRS types 1 and 2, acute heart injury (AHI) and chronic heart failure (CHF) precede acute kidney injury (AKI) and chronic kidney disease (CKD), respectively. Subtypes 3 and 4 showed the opposite with the kidney being the primary organ affected through AKI and CKD, leading to AHI and CHF. CRS type 5 describes both heart and kidney dysfunction that coexist as the result of other systemic diseases ([**Figure 1**](#f1){ref-type="fig"}). Since this classification system was proposed 12 years ago, it lacks a more precise definition owing to the complex interaction between the heart and the kidneys ([@B65]). The heart is the most important organ in the circulatory system and distributes nutrients and oxygen to other organs, including the kidney. The kidney is the major organ responsible for regulating salt and water balance of the whole body. For decades, it was believed that impaired cardiac function leads to low cardiac output and therefore decreases the kidney glomerular filtration rate (GFR). This renal dysfunction then results in increased fluid retention which in turn leads to increased cardiac pre- and afterload ([@B65]). However, it has been demonstrated that improving cardiac function in type 1 and type 2 CRS patients did not improve renal function ([@B62]). This discrepancy between theory and clinical observation underlines the notion that the underlying mechanisms of CRS still remain largely unknown. Nevertheless, the principle therapy for CRS, especially type 1 and type 2, is aimed at improving cardiac function. For example, using diuretics to reduce fluid overload and blood pressure is a common treatment option for CRS. However, such anti-hypertensive treatments require close monitoring since hypotension and renal hypoperfusion can lead to worsening of kidney function ([@B40]). Other treatments, such as angiotensin converting enzyme (ACE) inhibitors, vasodilators, and inotropic drugs, are also commonly used for treatment ([@B39]). In type 3 and type 4 CRS, inflammation caused by AKI or CKD leads to elevated cytokine expression and leukocyte infiltration in the heart ([@B9]; [@B19]; [@B44]; [@B1]; [@B14]). This may trigger cardiomyocyte apoptosis which in turn contributes to impaired cardiac function. In addition, fluid and electrolyte imbalance and uremia toxicity are also recognized as drivers of type 3 and type 4 CRS. Currently, there are no effective therapies specific for types 3 and 4 CRS and the only available option to use diuretics to improve fluid removal from the circulation ([@B13]; [@B15]). Systemic diseases, such as sepsis and diabetes mellitus (DM), are the main reason for type 5 CRS. Like other types of CRS, systemic diseases induce strong inflammatory responses which can impair both cardiac and renal function simultaneously. Therefore, the first therapeutic option is to treat the detrimental inflammation. This includes the use of antibiotics and inotropic drugs for sepsis patients, whereas insulin, to lower blood glucose levels, is given to DM patients ([@B72]).

![The role of miR-21 in cardiorenal syndrome. The underlying mechanisms of CRS are still unclear, and the current classification system for CRS is based on the clinical phenotype. Based on the primary organ dysfunction, CRS can be categorized into five subtypes. Under certain stress conditions (hypertension, LPS, or inflammation), the miR-21 is upregulated in **(A)** cardiac or **(B)** renal fibroblast and induces fibrosis. MiR-21 can also be transported by microvesicles to other cell types to induce fibrosis. **(C)** In SLE, the miR-21 is upregulated in both B and T cells which induces strong inflammation. Treatment of miR-21 ASOs could significantly alleviate the fibrosis and, therefore, improve the cardiac and renal function.](fphar-11-00726-g001){#f1}

MiRNAs and Their Role In Cardiorenal Syndrome {#s2}
=============================================

Owing to the rapid development of next-generation sequencing (NGS) technologies over the last decade, it became evident that vast parts of our genome are actively transcribed into non-coding RNAs (ncRNAs), while the protein coding transcripts, i.e., messenger RNAs (mRNAs), are transcribed by only 1% to 2% of the human genome ([@B74]; [@B4]). In addition to transfer RNAs (tRNAs) and ribosomal RNAs (rRNAs), the most well-known ncRNAs are long non-coding RNAs (lncRNAs) and microRNAs (miRNAs or miRs). MiRNAs are short, single-stranded, and highly conserved ncRNAs that widely exist in eukaryotes. MiRNAs are involved in several gene expression regulatory programs including mRNA degradation and translational repression *via* RNA interference (RNAi) mechanisms ([@B6]). MiRNAs are mainly transcribed by RNA polymerase II as pri-miR and subsequently processed by the RNase III endonucleases Drosha and Dicer ([@B18]). The mature 18 to 21 nucleotide miRNAs then bind immediately to Argonaute (AGO) proteins to form the RNA-induced silencing complex (RISC). Next, the seed region of the miRNA (normally the first 1--8 nucleotides) binds to the complementary site of the target mRNA which then induces RISC-mediated recruitment of suppression factors to inhibit protein translation. Through association with different proteins of the AGO family, the RISC can also directly degrade targeted mRNAs, while the endonuclease activity is specifically mediated by AGO2 ([@B5]). Several miRNAs have already been identified for their essential roles in heart and kidney disease ([@B11]; [@B75]; [@B16]; [@B56]; [@B57]; [@B61]; [@B58]; [@B83]; [@B84]; [@B28]; [@B77]; [@B79]; [@B85]; [@B63]). Many miRNAs are known to be involved to varying degrees in both the acute and chronic phases of primary organ dysfunction in CRS, however, miR-21 specifically has been reported in all types of CRS ([**Figure 1**](#f1){ref-type="fig"} and [**Table 1**](#T1){ref-type="table"}). Interestingly, miR-21 is highly expressed in the heart and kidneys and elevated levels of miR-21 lead to a poor outcome in most primary organ dysfunctions ([@B47]; [@B22]; [@B88]). Nevertheless, some studies also showed that miR-21 is a cardio- and reno-protective miRNA in acute disease states, such as acute myocardial infarction. Based on the association and promising preclinical data for antisense oligonucleotide (ASO)-mediated targeting of miR-21 in the heart and kidneys ([@B75]; [@B86]; [@B54]; [@B78]; [@B14]; [@B38]), suppression of miR-21 may represent an attractive therapeutic option for the treatment of CRS. In this mini review, we aim to give a concise overview of the role of miR-21 in different clinical manifestations of CRS. In addition, we summarize the current state of oligonucleotide-based drugs.

###### 

Other potential miRNAs that are involved in cardiorenal syndrome.

  Type   Primary dysfunctional organ                  Secondary dysfunctional organ           Related miRNAs             Reference
  ------ -------------------------------------------- --------------------------------------- -------------------------- --------------------------------------------------
  1      Acute heart injury                           Acute kidney injury                     miR-21, miR-208, miR-320   ([@B20]; [@B12]; [@B16]; [@B57]; [@B77]; [@B81])
  2      Chronic heart failure                        Chronic kidney disease                  miR-21, miR-22, miR-133    ([@B11]; [@B84]; [@B85])
  3      Acute kidney injury                          Cardiovascular disease                  miR-21, miR-20a, miR-24    ([@B75]; [@B34]; [@B58]; [@B77])
  4      Chronic kidney disease                       Chronic heart failure                   miR-21, miR-155, miR-29    ([@B61]; [@B28]; [@B14])
  5      Systemic disease (sepsis, DM, SLE ... etc)   Cardiac and renal dysfunction coexist   miR-21, miR122, miR-146a   ([@B56]; [@B79]; [@B63])

DM, diabetes mellitus; SLE, systemic lupus erythematosus

MiR-21 In Cardiac And Renal Dysfunction {#s3}
=======================================

MiR-21 in [H]{.ul}eart [D]{.ul}isease {#s3_1}
-------------------------------------

MiR-21 was first identified to be robustly up-regulated in cardiac hypertrophy and was later shown to be a cardiac fibroblast-derived miRNA ([**Figure 1**](#f1){ref-type="fig"}). MiR-21 suppresses *Sprouty homolog 1* (*Spry1)* expression, and thus enhances ERK-MAPK activity which leads to fibroblast activation/proliferation and cardiac fibrosis ([@B75]). Silencing of miR-21 by antagomir ASOs in the transverse aortic constriction (TAC) mouse model; efficiently blocks the ERK-MAPK signaling pathway, reduces interstitial fibrosis, and restores cardiac function. Interestingly, miR-21-3p, also known as the miR-21 passenger strand or miR-21\*, which was thought to be degraded during miRNA biosynthesis, can also regulate cardiac hypertrophy. Bang et al. showed that miR-21-5p (the guide strand) is enriched in cardiac fibroblasts, while miR-21-3p is enriched in fibroblast-derived exosomes ([**Figure 1**](#f1){ref-type="fig"}). By targeting *SORBS2* and *PDLIM5* through paracrine secretion to cardiomyocytes, miR-21 induces cardiac hypertrophy. Inhibition of miR-21-3p expression by an antagomir could reverse this phenotype ([@B2]). In addition to the modulation of fibrosis signaling pathways, Liang et al. demonstrated that TGF-β1 can directly activate miR-21 expression and further induce cardiac fibrosis through activating collagen and α-SMA protein expression; whereas inhibition of miR-21 reverses these alternative fibrosis pathways ([@B54]; [@B59]). Apart from directly inducing fibrosis, miR-21 has also been reported to participate in the endothelial--mesenchymal transition (EndMT), which indicates the multi-functional role of miR-21 in cardiac fibrosis ([@B48]; [@B33]).

Nevertheless, in an acute heart injury such as in the early phases of acute myocardial infarction (AMI) or ischemic preconditioning (IP), a temporary injury known to be cardioprotective, miR-21 appears to function differently between acute and chronic heart disease. A study conducted by Dong et al. showed that miR-21 expression decreased in the infarct area of the heart 6 h after AMI and increased 6 h after IP. Overexpression of miR-21 *via* an adenovirus significantly reduces infarct size and cardiomyocyte apoptosis. In contrast, inhibition of miR-21 by ASOs increased cardiomyocyte apoptosis and programmed cell death 4 (PDCD4) protein expression ([@B20]; [@B12]; [@B81]). This conflicting data indicates that varying conditions need to be taken into account when considering different treatments to target miR-21 such as: different cardiac cell types, the specific type of heart disease, and the state of disease progression.

MiR-21 in Kidney Disease {#s3_2}
------------------------

Similar to its role in heart disease, miR-21 contributes to the progression of acute and chronic stages in kidney disease and also has distinct roles in early and late disease stage ([@B38]). In some studies, AKI induced by ischemia reperfusion injury (IRI), activates massive inflammation, epithelial cell apoptosis, and fibrosis ([@B8]). During inflammation, macrophages activate miR-21 expression in renal fibroblasts through two pathways: 1) macrophages secrete high level of interleukin-6 (IL-6) which activate STAT3 and further induce miR-21 expression in renal fibroblasts; 2) macrophages secrete small extra-cellular vesicles enriched with miR-21 that are transferred to renal fibroblasts ([@B67]) ([**Figure 1**](#f1){ref-type="fig"}). These renal miR-21 levels inhibit Notch2 expression which induces increased fibrosis markers such as collagen 1 and α-SMA. Liu et al. also showed that miR-21 directly participates in renal fibrosis by targeting *DDAH1 (* [@B55] *)* which is a key gene involved in the pathological process of end-stage AKI. In other cases of ischemia/reperfusion-induced AKI, miR-21 was shown to be reno-protective. Song et al. showed that miR-21 protects the kidney from ischemia/reperfusion-induced AKI by preventing the apoptosis of renal epithelial cells and inhibiting an inflammatory response ([@B25]). Xu and colleagues also demonstrated that miR-21 was up-regulated after renal IP and attenuated IRI in the kidneys ([@B59]). Different from AKI, in a mouse model for diabetic nephropathy, miR-21 is mainly expressed in cortical glomerular and tubular cells and induces renal fibrosis which eventually leads to CKD ([@B78]). Inhibition of miR-21 by antagomir ASOs significantly decreased inflammation; cell apoptosis; and reduced collagen I, α-SMA, and fibronectin expression in a mouse model for diabetic nephropathy ([@B78]). In addition, TGF-β1 activates miR-21 expression, not only in cardiac fibroblasts, but also in renal tubular epithelial cells (TECs) through Smad3 activation ([@B86]). Suppression of Smad3 prevents TGF-β1-induced miR-21 expression, and thus prevents renal fibrosis. Moreover, direct silencing of miR-21 by antimir ASOs reduces fibrosis markers *in vivo* and *in vitro (* [@B86] *)*.

MiR-21 in Systemic Disease {#s3_3}
--------------------------

Inflammation is a common feature of systemic diseases; thus it is not surprising that miR-21 also plays an important role such diseases like sepsis, DM, hypertension, and systemic lupus erythematosus (SLE). In sepsis-induced cardiac dysfunction, Wang et al. showed that miR-21-3p is significantly up-regulated in the heart after lipopolysaccharide (LPS)-induced sepsis in mice. Similar to Bang and colleagues\' work, miR-21 altered the cardiac α/βMHC ratio and caused cardiac dysfunction through targeting *SORBS2*, while inhibition of miR-21 by antagomir ASOs improved cardiac function and prevented mitochondrial ultrastructure damage ([@B79]). In a type II DM mouse model, Zhong and colleagues showed that renal miR-21 expression increased compared to healthy mice. Zhong et al. further demonstrated that miR-21 inhibits *Smad7* expression which results in activation of TGF-β and NF-κB. Knockdown of miR-21 restores *Smad7* expression and ameliorated microalbuminuria, renal fibrosis, and inflammation ([@B87]). Hypertension is a major contributor to type 2 and type 4 CRS, Nohria et al. analyzed data from the ESCAPE Trial and found that patients with a history of hypertension and DM were associated with decreased renal function ([@B62]). However, using diuretics or ACE inhibitors to treat hypertension, cause side effects, such as hypotension, and therefore, reduced the renal afferent arteriole pressure and glomerular filtration rate ([@B39]). Additionally, Nohria et al. found that improving heart function did not further improve renal function. The current treatments of CRS are limited, and therefore require further research to develop drugs with new targets. Another systemic disease is SLE (or lupus), an autoimmune disease characterized by an excessive immune reaction against self-antigens. Auto-antibodies that are produced by hyperactive B cells and from defects in T cell-dependent B cell activation, are two major causes of SLE ([@B24]; [@B21]). It has been shown that miR-21 is up-regulated in lupus B and T cells, and the silencing of miR-21 with ASOs is able to significantly reverse splenomegaly, one of the clinical manifestations in SLE patients ([@B31]; [@B83]) ([**Figure 1**](#f1){ref-type="fig"}). Similarly, Garchow et al. induced SLE in miR-21 knockout mice and found a reduction of CD28:CD80/86 and CD40:CD154 co-stimulatory pathways which are responsible for initiating an immune response and for T cell activation ([@B30]).

MiRNA Inhibition By Antisense Oligonucleotides {#s4}
==============================================

Derailed expression of miRNAs and the subsequent functional consequences may be treated by novel RNA therapeutics. Endogenous downregulation can be compensated with synthetic miRNAs, known as miR-mimics, whereas increased expression can be blocked by single-stranded miRNA-specific antisense molecules. While both strategies have been successfully applied in numerous preclinical studies, the clinical use of miRNA therapeutics is still very challenging. RNAs are extremely sensitive and vulnerable to ribonuclease-mediated degradation, which is present in both cellular and extra cellular environments. These properties do not allow the use of "naked" antisense oligonucleotides (ASOs) *in vivo* since they will soon be degraded by ribonucleases in the bloodstream of the target organ ([@B52]; [@B80]). To circumvent this problem, chemically modified nucleotides are used to stabilize the ASOs. At the same time, certain modifications may also assist with their cellular uptake. In this context, Banks et al. demonstrated that phosphorothioate modified ASOs enter cells through membrane-bound receptors ([@B3]), however, most unmodified ASOs are taken up by cellular endocytosis ([@B43]). Currently, there are three major types of modifications: 1) Backbone modifications, 2) locked nucleic acids (LNA), and 3) Ribose 2′-OH group modifications ([@B50]; [@B66]).

Backbone Modifications: Phosphodiester, Phosphorothioate, Boranophosphate {#s4_1}
-------------------------------------------------------------------------

The first generation of modified ASOs are phosphorothioate-modified (PS)-ASOs which are characterized by a substitution of the non-bridged phosphate oxygens with Sulphur atoms. The PS-ASOs are highly resistant to nucleases and have high retention rates in the body due to their minimal clearance by the kidney and urinary excretion. However, a negative side effect is that PS-ASOs can also bind non-specifically to proteins, and thus may cause cytotoxicity ([@B36]; [@B45]).

Locked Nucleic Acids {#s4_2}
--------------------

Through a methylene bridge between the 2′-O and the 4′-C of the ribose, LNA-ASOs have a stable "locked" 3′-endo-conformation structure which allows them to be nuclease resistant. With this "locked" structure, LNA-ASOs can allow for more stable and much more specific binding to a target RNA. Notably, the pure LNA-ASO structure is not able to induce robust RNase-mediated cleavage of the ASO-miRNA hybrid, but instead, blocks the miRNA from binding to its target. To circumvent this issue, a short stretch of DNA (6--8 nucleotides) can by placed between two LNA structures ([@B49]). Such DNA/LNA mix-mers, called "GapmeR" form a short DNA-RNA hybrid between the short DNA and the targeted RNA which induces efficient cleavage by RNase H. Both single LNA- and GapmeR-modified ASOs could be used to inhibit miRNA expression. One can also combine two modifications to form an LNA-GapmeR ASO for the inhibition of most mRNAs, lncRNAs, and miRNAs ([@B49]; [@B23]).

Ribose 2′-OH Group: (2′-O-Me, 2′-F, 2′-O-MOE) {#s4_3}
---------------------------------------------

A ribose 2′-OH group modification is the second generation and best studied type of ASOs. By substituting the ribose 2′-OH group with other groups, such as 2′-O-methyl (2′-O-Me), 2′-fluoro (2′-F), and 2′-methoxyethyl (2′-O-MOE), the ribose-ASOs gain nuclease resistance, enhanced stability, and an increased half-life *in vivo*. In addition to nuclease resistance, ribose-ASOs have other advantages including higher specificity to their targeted RNA and reduced immune activation ([@B42]; [@B23]).

Importantly, all the modification mentioned above can also be combined to further enhance stability and specificity. For example, the miRNA inhibitor "antagomir" is an ASO that is modified with 2′-O-Me, PS, and a cholesterol group, which lends them better nuclease resistance, high specificity, and enhanced cellular uptake efficiency ([@B46]; [@B53]). Currently there are several ASOs in Phase I/II clinical trials ([@B29]; [@B69]) ([**Table 2**](#T2){ref-type="table"}), among them are Miravirsen and RG-012, which specifically target miR-122 and miR-21, respectively. MiR-122 is a liver-specific miRNA that is essential for hepatitis C virus (HCV) accumulation and replication ([@B41]). *In vitro* and *in vivo* treatment with Miravirsen, an ASO with both LNA and PS modifications, showed significant down-regulation of miR-122, reduction of interferon-regulated genes, and improvement of HCV-induced liver pathology ([@B51]; [@B32]). RG-012, which is modified with PS and 2′-O-MOE, is currently being tested as a cure for Alport syndrome. Alport syndrome is a kidney disease caused by mutations in collagen genes (*Col4A3, Col4A4*, and *Col4A5*). The basement membranes are assembled with collagen type IV, laminins, and proteoglycans. Six different genes (from *Col4A1* to *Col4A6*) encode six chains of collagen type IV (collagen IV α1 to α6), and of them, three chains (e.g. α3, α4, and α5) are assembled into one protomer. However, in Alport syndrome, the genes responsible for encoding collagen type IV are mutated. For example, the major mutation for the *Col4A5* gene is on chromosome Xq26--48, and for the *Col4A3* and *Col4A4* genes, the mutation is located on chromosome 2q35--37. These mutations prevent proper protomer assembly and, therefore, result in a defective glomerular basement membrane and kidney dysfunction ([@B40]). Patients of Alport syndrome suffer from kidney dysfunction, hearing loss, and eye abnormalities. Administration of RG-012 to inhibit miR-21 leads to a slowed progression of renal fibrosis and an increased lifespan in Alport syndrome mouse models ([@B35]).

###### 

Current ASOs in clinical trials.

  Drug                       Target    Indication                 Chemical modification   Phase                                    Reference
  -------------------------- --------- -------------------------- ----------------------- ---------------------------------------- ------------------
  **RG-012**                 miR-21    Alport syndrome            2′-O-MOE, PS            I/II                                     ([@B35])
  **Miravirsen (SPC3649)**   miR-122   Hepatitis C virus          LNA, PS                 ll                                       ([@B51]; [@B32])
  **RG-101**                 miR-122   Hepatitis C virus          GalNAc                  Terminated, metabolic/hepatic toxicity   ([@B76])
  **Cobomarsen (MRG-106)**   miR-155   CTCL (MF subtype)          LNA                     I/II                                     ([@B69])
  **S95010 (MRG-110)**       miR-92    Accelerate wound healing   LNA                     l                                        ([@B29])

CTCL, cutaneous T-cell lymphoma; MF, mycosis fungoides

Challenges In Aso Therapy {#s5}
=========================

Despite advances in development and therapeutic applicability, several challenges for ASO drugs still need to be solved ([@B27]; [@B76]) ([**Table 3**](#T3){ref-type="table"}). One challenge is to reduce the potential off-target effects of ASOs, but also to regulate undesired on-target effects that may represent an issue. For example, miR-21 is not organ or cell type-specific and has distinct functions depending on the organ and/or disease progression. Thus, a patient may suffer from undesired effects of miR-21 ASO therapy in one organ (e.g. the heart) despite successfully targeting of miR-21 in another organ (e.g. the kidney). This may even be the case in the very same organ where antisense treatment may be beneficial for one cell type (e.g. cardiomyocytes) and at the same time detrimental in another cell type (e.g. endothelial cells). To reduce off-target effects, careful dose-regulation studies are required to determine the optimal concentration ([@B71]). In addition, bioinformatics analysis for optimal and specific sequence design is another way to improve ASO specificity, although due the short sequences of miRNAs, the options are very limited in comparison to mRNAs or lncRNAs. The length of ASOs is another important factor for reducing off-target effects. Yoshida et al. found that ASOs with at least 13-mer in length show a higher specificity. Thus, it is conceivable that that the shorter the ASO, the higher the number of complementary regions for unintended off-target RNAs ([@B82]). For instance, Miravirsen is a 15-mer ASO which is sufficiently long enough to minimize the potential off-target effects. A further challenge is immunostimulatory effects that can be caused by the chemical modifications of ASOs. It has been shown that a 2′-O-MOE modification induces pro-inflammatory responses including elevated cytokine levels and immune cell infiltration in the liver ([@B68]). Moreover, potential hepatic and renal toxicity are known issues. Burdick et al. showed that LNA-ASOs with certain sequence motifs (TCC and TGC), cause hepatotoxicity indicated by liver lesions ([@B10]). Renal toxicity such as glomerulopathy has also been reported in some cases; however, the control group in these studies is phosphate buffer saline (PBS) as opposed to ASO-scramble which did not explain whether the renal toxicity arose from ASO-mediated gene inhibition or the structure/chemical modification of the ASO itself. Therefore, the relationship between renal toxicity and ASOs is still unclear and warrants further investigation ([@B37]; [@B26]). A recent study assessed 11 different ASOs that had been tested in 32 clinical trials; here the authors found no evidence for renal dysfunction in ASO-treated patients ([@B17]). Nevertheless, hepatic and renal functions should be closely monitored, especially when giving ASO drugs to CRS patients. Finally, the delivery of the ASO drug to disease-specific sites also represents big hurdles for RNA-based therapeutic strategies. The systemic delivery of ASOs does not allow for exclusive targeting of the diseased organ, while organ-specific delivery requires invasive procedures. In the same context, despite the various modifications of ASOs, their often-inefficient penetration of the cell membrane\'s lipid bilayer remains an issue. To achieve better cellular uptake, there are two major delivery systems for ASOs under intense investigation which involve the packaging of ASOs into polymer- and lipid-based nanoparticles ([@B52]; [@B80]). Furthermore, ASOs may also be delivered through conjugation with antibodies ([@B60]). In particular the latter seems to have a good clinical prospect given that cell surface-specific antigens for the target cell type can be identified.

###### 

Possible side effects and solutions in ASO therapy.

  Side effects            Cause                     Solutions
  ----------------------- ------------------------- ------------------------------------------------------------
  **Off-target**          Organ non-specific        Organ specific delivery method
                                                    Dosage test to find optimal concentration
                          Non-specific binding      Improve bioinformatics analysis
                          ASO with short sequence   Increase the length to 13 to 15-mer
  **Immunostimulatory**   Chemical modification     Avoid the known modifications that cause immunostimulation
  **Organ toxicity**      Toxic motif (TCC/TGC)     Avoid toxic motif when designing ASO

Current treatments for CRS are mainly small molecule drugs. ASOs that specifically inhibit miR-21 expression could be promising drugs for CRS through attenuating cardiac and renal fibrosis. Potential off-target, inflammatory response, and hepatic/renal toxicity of ASOs are the main challenges in an ASO-based therapy and need to be monitored carefully.

Summary and Outlook {#s6}
===================

With an increased level of concrete preclinical evidence, more clinical trials for ASO-based therapies are ongoing and several ASO-based drugs are already FDA approved ([@B73]). Here, we summarized the current knowledge on the role of miR-21 mostly in primary dysfunctional organs, such as the heart and the kidneys. However, since both organs are affected in complex and not yet fully understood mechanisms in CRS, more experiments need to be performed in an appropriate and practical CRS model. Chuppa et al. demonstrated that suppression of miR-21 improved cardiac function in type 4 CRS ([@B14]) and Rana et al. showed that miR-21 expression positively correlated with uremic toxin levels (urea, creatinine, phenols etc.) in type 2 CRS. Treatment with AST-120, an orally administered intestinal sorbent that lowers serum uremic toxins, attenuated cardiac fibrosis and down-regulated miR-21 expression. An ASO targeting miR-21 taken with AST-120 again reinforces the notion that miR-21 may be a promising therapeutic target in the treatment of CRS ([@B64]). Recently, a treatment of antimiR-132 in patients with heart failure, which is a trigger for type 2 CRS, also went into first-in-human trials (NCT04045405) ([@B25]). With the remarkable progress in genome sequencing, personalized medicine, and gene and ASO therapies, there are now novel innovative therapeutic strategies available that add up to the repertoire of traditional small molecule or protein based drugs. Nevertheless, continuous research is needed to further improve ASO chemical modifications, target specificity, and to determine optimal delivery routes and drug dosing. With this in mind, we are hopeful that more ASO-based drugs will enter the market in the near future, eventually including those that could treat CRS.
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